LumiSTAR Biotech

What LumiSTAR Biotech does

LumiSTAR Biotechnology, Inc. is a Taiwan-based, privately held biotech company that develops induced pluripotent stem cell (iPSC)-derived cells, genetically encoded fluorescent biosensors, and contract research services for drug discovery and cell therapy development. The company's core platform integrates three proprietary capabilities: an iPSC technology platform that produces differentiated human cell types (cardiomyocytes, cortical neurons, GABAergic neurons, microglia, and astrocytes) including patient-specific disease models carrying familial Alzheimer's mutations (PSEN1 A246E, APP V717I); a viral delivery system engineered for high-efficiency, low-cytotoxicity transduction; and the LumiRDT biosensor portfolio, comprising the Painter series for organelle labeling and the Flash series for calcium and reactive oxygen species detection. The LumiRDT platform is positioned for long-term, real-time cellular monitoring on the order of weeks to months, contrasting with conventional chemical probes that function for hours. Products are marketed under the LumiStem™ (iPSC-derived cells) and LumiRDT® (biosensors) sub-brands.

LumiSTAR operates four revenue streams: one-time sales of catalog iPSC-derived cells and LumiRDT biosensor reagents, contract research services covering high-throughput screening, iPSC disease modeling, cardiotoxicity testing, and neurotoxicity testing, and a technology out-licensing program covering iPSC lines, differentiation protocols, biosensor distribution rights, and integrated screening platform packages. Customer segments span pharmaceutical and biotech companies, academic and research institutions, and contract research organizations, with pain points centered on preclinical toxicity prediction, human-relevance of disease models, and limitations of chemical fluorescent dyes.

The company is headquartered in Taipei's National Biotechnology Research Park, with a second R&D site at Taipei Bioinnovation Park. Go-to-market combines direct enterprise sales (including a Director of Sales and Marketing) with a regional distributor network: KimForest Enterprise (Taiwan), AllisWell Bio and Pentagon Technology (regional), AS ONE Corporation (Japan), and Carrigent (United States). Strategic 2025 partnerships with Aivita Wellness Clinic and Aivita Health Group extend the footprint into the Middle East and India through a Smart Cell Therapy Hub in Dubai and regenerative medicine commercialization. Leadership comprises PhD-credentialed founders Yu-Feng Chang (CEO, ex-Oxford BHF Fellow) and Min-Wen Chung (COO, Oxford Clarendon scholar), with CFO Catherine Tsai — a biotech VC — as the company's first angel investor, and CTO Shiu-Mei Wang leading the virology platform. Beyond research tools, LumiSTAR is advancing a two-program pre-clinical cell therapy pipeline targeting Alzheimer's disease (NIPS-NP) and chronic kidney disease (FIPS-RP).

Name

LumiSTAR Biotech

Legal name

LumiSTAR Biotechnology, Inc.

Website

https://lumistarbiotech.com

Company type

Private

Operating status

Operating

Short description

LumiSTAR Biotech is a Taiwan-based private biotech that develops iPSC-derived cells (LumiStem™), genetically encoded fluorescent biosensors (LumiRDT®), and contract research services for pharmaceutical companies, academic researchers, and CROs engaged in drug discovery, toxicity testing, and cell therapy development.

Ownership category

akta.pro rank

Product category

iPSC-Derived Cells and Biosensors for Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• IPSC cell therapy
• Drug discovery services
• Genetically encoded biosensors
• Cardiotoxicity testing
• Patient-specific disease modeling

Headquarters

HQ city

Taipei City

HQ country

Taiwan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. iPSC-Derived Cell Products: Sale of off-the-shelf iPSC-derived cells including cardiomyocytes, neurons, astrocytes, and microglia. LumiStem branded products are sold directly to researchers and pharmaceutical companies for drug discovery, toxicity screening, and disease modeling applications.
2. LumiRDT Biosensor Products: Sale of LumiRDT genetically encoded biosensor reagents (Painter and Flash series) as ready-to-use viral reagents for live-cell imaging and real-time cellular monitoring. Sold as catalog products with specific organelle and function targeting options.
3. Contract Research Services: End-to-end contract research services combining iPSC technology with LumiRDT biosensors. Services include high-throughput screening, iPSC disease modeling, cardiotoxicity testing, and neurotoxicity testing. Designed to accelerate R&D programs for pharmaceutical and biotech clients while reducing costs and risks.
4. Technology Out-Licensing: Licensing of proprietary technology assets including iPSC lines, differentiation protocols, disease modeling methods, LumiRDT biosensor distribution rights, and integrated screening platform packages (hardware integration, software algorithms, assay protocols). Partners can access technology across various regions or sectors.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels5 records

Core offering

LumiSTAR Biotech develops and sells iPSC-derived human cells (cardiomyocytes, neurons, astrocytes, microglia), LumiRDT genetically encoded fluorescent biosensors for live-cell imaging, and contract research services for drug discovery, cardiotoxicity, neurotoxicity, and disease modeling. The company also out-licenses its iPSC lines, differentiation protocols, and biosensor technology to partners globally.

Product overview

LumiSTAR Biotech offers a platform-based portfolio combining iPSC-derived cells and genetically encoded biosensor technology. The core products include the LumiStem™ iPSC-derived cell family (cardiomyocytes, cortical neurons with disease mutations, GABAergic neurons, microglia, and astrocytes) and the LumiRDT® biosensor platform (Painter Series for organelle labeling and Flash Series for calcium/ROS detection). These products are complemented by contracted research services and technology out-licensing, enabling applications from drug discovery and toxicity testing to regenerative medicine development.

Differentiator

Problem solved

Functional benefit

Brands

• LumiStem™: iPSC-derived cell product line including cardiomyocytes, cortical neurons, GABAergic neurons, microglia, and astrocytes for drug discovery and toxicity evaluation.
• LumiRDT®

Products and services

• LumiStem Cardiomyocytes (iCM003) Human iPSC-derived ventricular cardiomyocytes with spontaneous beating, mature calcium handling, and stable electrophysiology for drug discovery and cardiotoxicity testing.
• LumiStem Cortical Neurons (LumiCR03) Human iPSC-derived wild-type cortical neurons forming functional excitatory networks with mature synaptic activity for neurodegenerative disease modeling.
• LumiStem Cortical Neurons PSEN1 A246E (LumiCR02) Human iPSC-derived cortical neurons carrying the PSEN1 A246E familial Alzheimer's mutation with altered amyloid processing phenotype.
• LumiStem Cortical Neurons APP V717I (LumiCR05) Human iPSC-derived cortical neurons harboring the APP V717I familial Alzheimer's mutation with elevated Aβ42/40 ratios.
• LumiStem GABAergic Neurons (LumiGR01) mCherry-tagged human iPSC-derived precursors that mature into functional inhibitory neurons with real-time fluorescent tracking.
• LumiStem Microglia (LumiMG01) Human iPSC-derived microglia with native immune surveillance, phagocytic activity, and cytokine responsiveness.
• LumiStem Astrocytes (LumiAC01) Human iPSC-derived astrocytes with functional glutamate uptake, calcium signaling, and neurotrophic support.
• LumiRDT Painter Series Genetically encoded fluorescent labels delivered as ready-to-use viral reagents for live-cell imaging, highlighting subcellular structures including Actin, Cytoplasm, Nucleus, Mitochondria, Golgi, ER, Endosomes, Lysosomes, Peroxisomes, Plasma membrane, and Tubulin in multiple colors.
• LumiRDT Flash Series Genetically encoded biosensors for illuminating calcium ions (Ca2+) and reactive oxygen species (ROS) in live cells, with organelle-specific targeting (ER, mitochondria, cytoplasm) and multiple colors (Calcium Red/Green/Blue/Far Red and Redox sensor) for real-time, long-term monitoring of organoid health and maturation.
• Contract Research Services End-to-end contract research services including High-Throughput Screening, iPSC Disease Modeling, Cardiotoxicity Testing, and Neurotoxicity Testing using LumiSTAR's integrated iPSC and LumiRDT biosensor platform, designed to accelerate R&D programs for pharmaceutical and biotech clients while reducing costs and risks.
• Technology Out-Licensing Out-licensing program offering access to proprietary iPSC technology, LumiRDT biosensor distribution rights, differentiation protocols, disease modeling methods, and integrated screening platform packages including hardware integration, software algorithms, and assay protocols.

Quantifiable outcome

• Long-term cellular monitoring extending from weeks to months compared to hours for conventional chemical probes
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core and regional.

• Aivita Wellness CliniccoreStrategic or Co-development Partner · 1 January 2025LumiSTAR and Aivita Wellness Clinic launched a regenerative medicine collaboration in Dubai, building a Smart Cell Therapy Hub in the Middle East. The partnership aims to advance high-end regenerative medicine applications using LumiSTAR's iPSC technology and automated cell manufacturing capabilities.
• Aivita Health GroupcoreStrategic or Co-development Partner · 1 January 2025Strategic alliance targeting high-end regenerative medicine markets in the Middle East and India. The partnership combines LumiSTAR's iPSC technology and automated cell manufacturing with Aivita Health Group's regional market presence and distribution capabilities.
• KimForest Enterprise Co., Ltd.regionalChannel Partner/ Reseller/ DistributorRegional distributor covering Taiwan for LumiSTAR's iPSC-derived cells and LumiRDT biosensor products. KimForest Enterprise distributes to end customers in Taiwan through its established local network.
• AS ONE CorporationregionalChannel Partner/ Reseller/ DistributorRegional distributor covering Japan for LumiSTAR's products, leveraging AS ONE Corporation's established distribution network in the Japanese life sciences market.
• CarrigentregionalChannel Partner/ Reseller/ DistributorRegional distributor covering the United States for LumiSTAR's products, enabling access to the North American market through Carrigent's local presence.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• FUJIFILM Cellular Dynamics International: Largest commercial supplier of iPSC-derived cells including cardiomyocytes, neurons, and hepatocytes for drug discovery and toxicity testing. Most direct competitor to LumiSTAR's LumiStem product line across essentially the same customer base of pharma and academic researchers.
• STEMCELL Technologies: Major supplier of iPSC culture media, differentiation kits, and cell products. Competes directly with LumiSTAR in providing tools for iPSC-derived cell workflows across pharma and academic drug discovery customers.
• Reprocell: Japan-based supplier of iPSC-derived cells and regenerative medicine products with established presence in Asia-Pacific markets. Particularly relevant peer for LumiSTAR given overlapping geographic focus and similar iPSC product portfolios.
• Axol Bioscience: UK-based supplier of iPSC-derived cells specializing in neural and cardiac disease models. Direct competitor in the same customer segments for neurodegenerative and cardiotoxicity research applications.

Broad incumbents

• Lonza: Global cell therapy and biological products manufacturer offering iPSC-derived cells and contract manufacturing services. Competes with LumiSTAR in iPSC tools while also offering broader CDMO capabilities that LumiSTAR cannot match.
• Thermo Fisher Scientific: Through its Gibco brand and acquired platforms, offers iPSC-derived cells, culture media, and biosensor reagents. Competes with LumiSTAR across both the cell products (LumiStem) and biosensor (LumiRDT) product lines as part of a much larger life sciences portfolio.

Emerging players

• BrainXell: Specialized supplier of iPSC-derived neurons and glia for neuroscience research and drug discovery. Overlaps directly with LumiSTAR's neural product line including cortical neurons, GABAergic neurons, microglia, and astrocytes.
• Evotec: Contract research organization offering iPSC-based drug discovery and toxicity screening services. Competes with LumiSTAR's contract research services arm for pharma outsourcing budgets in preclinical drug discovery.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lumistar-biotechnology

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LumiSTAR Biotech